Literature DB >> 16732136

Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.

Sheldon H Preskorn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16732136     DOI： 10.1097/00131746-200605000-00006

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN： 1527-4160            Impact factor:   1.325


× No keyword cloud information.
  5 in total

1.  Emsam: the first year.

Authors:  Elisa F Cascade; Amir H Kalali; Sheldon H Preskorn
Journal:  Psychiatry (Edgmont)       Date:  2007-06

2.  Selegiline transdermal system in major depressive disorder: profile report.

Authors:  James E Frampton; Greg L Plosker
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.

Authors:  Vincent Van den Eynde; Peter Kenneth Gillman; Barry B Blackwell
Journal:  Psychopharmacol Bull       Date:  2022-05-31

4.  Selegiline transdermal system: in the treatment of major depressive disorder.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.